Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease

We retrospectively reviewed 20 consecutive patients with Alzheimer's disease who switched from lecanemab to donanemab. No new amyloid-related imaging abnormalities (ARIA) or significant adverse events were observed during the first five donanemab infusions. Prior exposure to lecanemab may reduce ARIA risk. Cognitive function remained stable. These preliminary observations suggest that switching between anti-amyloid therapies may be safe in the short term, though larger prospective studies are warranted.